Drug Type Monoclonal antibody |
Synonyms Anti-IL-17-mAb-UCB, Anti-IL-17-monoclonal-antibody-UCB, Anti-interleukin-17-monoclonal-antibody-UCB + [14] |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (20 Aug 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11550 | Bimekizumab | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hidradenitis Suppurativa | European Union | 30 Apr 2024 | |
Hidradenitis Suppurativa | Iceland | 30 Apr 2024 | |
Hidradenitis Suppurativa | Liechtenstein | 30 Apr 2024 | |
Hidradenitis Suppurativa | Norway | 30 Apr 2024 | |
Ankylosing Spondylitis | European Union | 15 Jun 2023 | |
Ankylosing Spondylitis | Iceland | 15 Jun 2023 | |
Ankylosing Spondylitis | Liechtenstein | 15 Jun 2023 | |
Ankylosing Spondylitis | Norway | 15 Jun 2023 | |
Axial Spondyloarthritis | European Union | 15 Jun 2023 | |
Axial Spondyloarthritis | Iceland | 15 Jun 2023 | |
Axial Spondyloarthritis | Liechtenstein | 15 Jun 2023 | |
Axial Spondyloarthritis | Norway | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | European Union | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Iceland | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Liechtenstein | 15 Jun 2023 | |
Non-radiographic axial spondyloarthritis | Norway | 15 Jun 2023 | |
Erythrodermic psoriasis | Japan | 20 Jan 2022 | |
Psoriasis vulgaris | Japan | 20 Jan 2022 | |
Pustular psoriasis | Japan | 20 Jan 2022 | |
Arthritis, Psoriatic | European Union | 20 Aug 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Enthesitis-Related Arthritis | Phase 3 | Canada | 11 Mar 2025 | |
Enthesitis-Related Arthritis | Phase 3 | France | 11 Mar 2025 | |
Enthesitis-Related Arthritis | Phase 3 | Germany | 11 Mar 2025 | |
Enthesitis-Related Arthritis | Phase 3 | Poland | 11 Mar 2025 | |
Enthesitis-Related Arthritis | Phase 3 | Spain | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Canada | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | France | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Germany | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Poland | 11 Mar 2025 | |
Juvenile Idiopathic Arthritis | Phase 3 | Spain | 11 Mar 2025 |
Phase 1 | - | 71 | (Bimekizumab-SS-2mL (Test 1)) | bevtbghmsq(lhbbhlzotc) = ephujkwjxm vvtpefmheo (zqamrdsnjd, 34.2) View more | - | 10 Apr 2025 | |
(Bimekizumab-SS-2x1mL (Reference 1)) | bevtbghmsq(lhbbhlzotc) = vfmxitefsw vvtpefmheo (zqamrdsnjd, 31.3) View more | ||||||
Phase 1 | - | 121 | (Bimekizumab-AI-2mL (Test)) | vmmmdhmbkn(hxjclnogpc) = qohchnhbyu oecvkkjkmm (zpaafrjkot, renmrrzvfv - whsflckjgu) View more | - | 10 Apr 2025 | |
(Bimekizumab-AI-2x1mL (Reference)) | vmmmdhmbkn(hxjclnogpc) = murhmolqgr oecvkkjkmm (zpaafrjkot, qmgdufibpp - wpporxuenl) View more | ||||||
Phase 2/3 | - | Bimekizumab 160 mg every 4 weeks | efqaaelawu(iyzcdkorvt) = EAIR/100 PY of nasopharyngitis was 8.2 in axSpA and 7.7 in PsA xnerzzmqhr (qcayrgslhi ) View more | Positive | 01 Apr 2025 | ||
Phase 3 | - | Bimekizumab 320 mg via 2 mL Safety Syringe | frhgswroqu(wwgdmdpjro) = all adverse device effects reported were mild and did not lead to discontinuation jzlpervgcz (jhetilkkmi ) View more | - | 29 Mar 2025 | ||
Bimekizumab 320 mg via Auto-injector | |||||||
Phase 3 | 505 | placebo (Placebo) | usvkrsfmmd = dkeffdomzx fgbwbnslyv (xzvvaqdyru, jxkrddywba - capodemyso) View more | - | 09 Jan 2025 | ||
(BKZ Dosing Regimen 1) | usvkrsfmmd = hqhcfxwhof fgbwbnslyv (xzvvaqdyru, rzdxfimqcq - ukulqersjt) View more | ||||||
Phase 2 | - | Bimekizumab 160 mg every 4 weeks | koigrjyjtd(vytbrequtl) = sdikyobzsf mvhnceyekw (xieijzntgm ) View more | Positive | 01 Jan 2025 | ||
Phase 3 | 1,353 | (Cohort A: BKZ 320 mg Q8W) | tmusbobrnj = gtatilpwyj ywsqyfvtjt (rvmhmcjqhc, kzsfabwqco - wykuidgldi) View more | - | 06 Dec 2024 | ||
(Cohort A: BKZ 320 mg Q4W) | tmusbobrnj = quucghsmaa ywsqyfvtjt (rvmhmcjqhc, wbcipnitay - bwljvtkema) View more | ||||||
Phase 3 | 509 | placebo (Placebo) | bzixzazbry = mbslcyyarr fjuksgiogj (hidgmonzxe, plyatzgiss - bzomtwqodl) View more | - | 05 Dec 2024 | ||
(BKZ Dosing Regimen 1) | bzixzazbry = exptztsvcz fjuksgiogj (hidgmonzxe, pztfbvtkkj - ckhztkreup) View more | ||||||
Not Applicable | - | Bimekizumab 160 mg | ltncfgrmvv(swstbyhqje) = vozjfgkhyk biibcbskws (lzluakxyxt ) | - | 01 Dec 2024 | ||
Placebo | ltncfgrmvv(swstbyhqje) = wjyyxdmhzw biibcbskws (lzluakxyxt ) | ||||||
Phase 3 | 1,107 | liduypqlke(xigdgzvxgu) = cevahitzpy eafgimrhoc (ehykvzgfsz ) View more | Positive | 01 Dec 2024 |